Skip to main content

Table 2 Clinical characteristics of the subjects with telbivudine therapy (n = 6)

From: Involvement of soluble scavenger receptor A in suppression of T cell activation in patients with chronic hepatitis B

Treatment week

Variable

0

12

24

HBV-DNA(log10 copies/mL)

8.64 (6.84-9.18)

5.06 (3.30-6.09)

3.86 (2.46-5.38)

ALT(U/L)

63.0 (15.0-147.0)

31.0 (21.0-79.0)

29.0 (17.0-51.0)

TBil (μmol/L)

14.4 (5.5-14.9)

14.8 (7.7-27.7)

18.4 (6.5-25.4)

SRA(ng/mL)

10.4 (9.3-21.2)

16.19 (8.7-19.8)

7.6 (4.2-9.7)

  1. Data are shown as median (10–90% percentile). TBil, total serum bilirubin.
Back to article page

BMC Immunology

ISSN: 1471-2172

Contact us